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Natural products that contain the tetramic acid motif have been studied extensively, and their complexity and biological profiles have led to several total syntheses.[1](#bib1){ref-type="ref"} For example, equisetin, a close structural analogue of the compounds studied here, has been prepared.[1a](#bib1a){ref-type="ref"}--[c](#bib1c){ref-type="ref"} However, the synthesis of members of a subfamily that contain an unnatural 4,4‐disubstituted glutamic acid unit (**1**--**4**, Figure [1](#fig1){ref-type="fig"}) is an unmet challenge.[2](#bib2){ref-type="ref"} The biological activity displayed by members of this subfamily justifies the development of a concise and general approach for their synthesis.

![A subfamily of tetramic acid natural products containing an unnatural 4,4‐disubstituted glutamic acid unit. Syntheses of **1**--**4** have not been reported thus far. The shown relative and absolute stereochemistry of **2** was assigned by our study.](ANGE-127-4118-g001){#fig1}

Examples of the important activity shown by this subfamily include the inhibition of the CCR5 receptor by Sch210972 (**1**).[2a](#bib2a){ref-type="ref"},[b](#bib2b){ref-type="ref"} A number of CCR5 receptor antagonists are in clinical trials or in use as antiretroviral drugs.[3](#bib3){ref-type="ref"}, [4](#bib4){ref-type="ref"} In addition, JBIR‐22 (**2**) is the first example of a tetramic acid that acts as a protein--protein interaction (PPI) inhibitor.[2c](#bib2c){ref-type="ref"},[d](#bib2d){ref-type="ref"} Compound **2** inhibits the homodimerization of the proteasome assembly chaperone 3 (PAC3), an important protein involved in the formation of the proteasomal machinery. The clinical success of bortexomib,[5](#bib5){ref-type="ref"} a proteasome inhibitor, supports the study of compounds that target the proteasome or its formation. The fact that the stereochemical assignment of **2** [2c](#bib2c){ref-type="ref"} was incomplete when our work began further highlights the need for synthetic studies on this subfamily of tetramic acids.

Although chemical[6](#bib6){ref-type="ref"} and enzymatic[7](#bib7){ref-type="ref"} syntheses of 4‐hydroxy‐4‐methylglutamic acid have been developed, a synthesis of 4‐hydroxy‐4‐*iso*‐propylglutamic acid has not yet been reported, which could be a factor in the lack of synthetic work done on this subfamily. Here we report a short, stereoselective synthesis of a 4,4‐disubstituted glutamic acid derivative and the application of this methodology to the first total synthesis of **2**. Our studies enabled the assignment of the relative and absolute stereochemistry of **2**.

Our initial synthetic plan was based on the synthesis of 1,3‐amino alcohols (e.g. **5**). This methodology involved the diastereoselective addition of a metalloenamine **6** to an aldehyde followed by diastereoselective imine reduction (Scheme [1](#sch1){ref-type="fig"}).[8](#bib8){ref-type="ref"} We proposed that the reaction of **7** with ethyl dimethylpyruvate could establish the required stereogenic center of the tertiary alcohol. Subsequent diastereoselective reduction of the resulting β‐hydroxy‐*N*‐sulfinyl ketimine **8** could give **9**, a precursor of a protected form of the unnatural amino acid **10** (Scheme [1](#sch1){ref-type="fig"}). If accessible, **10** could potentially be used in the synthesis of **2** in an analogous manner to that previously demonstrated for other tetramic acids containing natural amino acids, such as equisetin.[1a](#bib1a){ref-type="ref"}--[c](#bib1c){ref-type="ref"}, [9](#bib9){ref-type="ref"} It also seemed plausible that the tertiary alcohol in **8** or **9** may cyclize to generate a lactone (e.g. **11** from **9**). If this occurred, *N*‐methylation of **11** and removal of the *N*‐sulfinyl group could give the masked 4,4‐disubstituted glutamic acid derivative **12**. Conversion of **12** to members of this subfamily was considered achievable.

![Ellman's stereoselective synthesis of 1,3‐amino alcohols.[8](#bib8){ref-type="ref"} A possible synthesis of the required unnatural amino acid or a cyclized version. Reagents and conditions: a) diastereoselective aldol reaction; b) diastereoselective reduction; c) lactonization; d) *N*‐methylation and cleavage of the *N*‐sulfinyl group; e) *N*‐methylation and protecting group manipulation.](ANGE-127-4118-g006){#sch1}

The synthesis of **7** was achieved by condensation of (*R~S~*)‐*tert*‐butanesulfinamide with ethyl pyruvate (**8**). Using the reported conditions,[10](#bib10){ref-type="ref"} **7** was obtained in only 30 % yield with the major product being lactone **13** (**13**:**7**=5:3, Scheme [2](#sch2){ref-type="fig"}). The formation of **13** likely occurred in situ through an Ti(OEt)~4~‐catalyzed aldol reaction of **7** with ethyl pyruvate (**8**) followed by lactonization (Scheme S1). Although **13** was not required for the preparation of **2**, it could be used in a future synthesis of **1**. Optimization of the synthesis of **7** resulted in its isolation in 60 % yield (Table S1). Reaction of **7** with ethyl dimethylpyruvate gave the related lactone **14** (Scheme [2](#sch2){ref-type="fig"}) with excellent diastereoselectivity and yield. As expected, **14** was confirmed as the (*Rs*,2*S*) diastereomer by X‐ray analysis (Scheme [2](#sch2){ref-type="fig"}).[8](#bib8){ref-type="ref"}, [11](#bib11){ref-type="ref"} *N*‐methylation of **14** proceeded in high yield to provide **15**. While an initial screening of reducing agents gave only recovered lactone **15**, the use of NaBH~3~CN with HCl (4 [n]{.smallcaps} in dioxane) resulted in the diastereoselective (d.r.\>98 %) reduction of **15** with cleavage of the *N*‐sulfinyl group to give **12** (Scheme [2](#sch2){ref-type="fig"}). The stereochemistry of **12** was assigned by NOE analysis (Scheme [2](#sch2){ref-type="fig"} and Figure S1). Further analysis suggested that this reaction proceeded by acid deprotection of the *N*‐sulfinyl group followed by the reduction with NaBH~3~CN (Scheme S2). The observed diastereoselectivity was rationalized based on the preferred approach of the reducing agent from the same side as the ester. This efficient route provided the masked 4‐hydroxy‐4‐*iso*propyl glutamic acid **12** in just four steps from **8**.

![Condensation of **8** and (*R~S~*)‐*tert*‐butanesulfinamide gave lactone **13** and **7** in a 5:3 ratio. Reagents and conditions: a) (*R~S~*)‐*tert*‐butanesulfinamide, Ti(OEt)~4~, Table S1 for optimization; b) (i) LDA, THF, 0 °C. (ii) Ethyl dimethylpyruvate, ZnBr~2~, −78 °C, 88 %, d.r.\>98 %; c) LiHMDS, iodomethane, DMF, −15 °C→RT, 95 %; d) (i) HCl (4 [n]{.smallcaps} in dioxane), THF, 0 °C, 10 min. (ii) NaBH~3~CN, MeOH, 1.5 h, 0 °C, 85 %, d.r.\>98 %. X‐ray analysis of **14** confirmed the expected (*Rs*,2*S*) stereochemistry. The stereochemistry of **12** was determined using NOE analysis (Figure S1).](ANGE-127-4118-g009){#sch2}

With **12** in hand, a synthesis of **2** was attempted because of its unique activity as a PPI inhibitor and the uncertainty associated with its stereochemical assignment. Izumikawa et al. had shown that **2** could be assigned as one of the four stereoisomers shown in Table [1](#tbl1){ref-type="table-wrap"} (diastereomers **2 a** and **2 b** and their enantiomers **2 c** and **2 d**).[2c](#bib2c){ref-type="ref"} Given the relatively large distance between the decalin moiety and the unnatural amino acid stereogenic center in **2**, it is difficult to assign the relative configuration of these two units. A convergent route to access optically enriched samples of diastereomers **2 a** and **2 b** was therefore investigated (Scheme [3](#sch3){ref-type="fig"}).

![Retrosynthetic analysis of JBIR‐22 diastereomer **2 a**.](ANGE-127-4118-g008){#sch3}

###### 

Stereochemical assignment of four of the possible stereoisomers of **2** (as reported in reference \[2c\]).^\[a\]^ The absolute configuration of stereoisomer **2 a** is depicted.

  ----------- ------------- -------------------------- --------------
  WILEY-VCH     Compound     Glutamic acid side chain   Decalin ring
  **2 a**      5′*S*,7′*S*     2*S*,3*S*,6*R*,11*S*    
  **2 b**      5′*S*,7′*S*     2*R*,3*R*,6*S*,11*R*    
  **2 c**      5′*R*,7′*R*     2*R*,3*R*,6*S*,11*R*    
  **2 d**      5′*R*,7′*R*     2*S*,3*S*,6*R*,11*S*    
  ----------- ------------- -------------------------- --------------

WILEY-VCH

The tetramic acid core in **2 a** would be formed at a late stage, inspired by the conversion of 3‐oxo‐homoserine lactones to simple tetramic acids through a Claisen‐like intramolecular reaction (Scheme S3).[12](#bib12){ref-type="ref"} A Lacey--Dieckmann condensation of fragment **16** would form the tetramic acid core and provide the unnatural 4,4‐disubstituted glutamic acid side chain in one step. Fragment **16** could be accessible through the coupling of **12** and the β‐ketothioester **17 a**. A late‐stage convergent step such as this could ultimately facilitate the coupling of alternate β‐ketothioesters to enable access to the other members of this subfamily (Figure [1](#fig1){ref-type="fig"}) or novel analogues. We envisaged that the decalin β‐ketothioester could be assembled through an asymmetric Diels--Alder cycloaddition followed by manipulation to introduce the thioester functionality (Schemes [4](#sch4){ref-type="fig"} and [5](#sch5){ref-type="fig"}).

![Synthesis of **23**. Reagents and conditions: a) KHMDS, diethyl 2‐butenylphosphonate (**19**), DME, −78 °C→RT, 69 %, *E*:*Z*=8:1; b) Aq. HCl, THF, RT, 12 h, 94 %; c) (i) (1,3‐dioxolan‐2‐ylmethyl)triphenylphosphonium bromide (**22**), *t*BuOK, THF, 0 °C, 3.5 h. (ii) 10 % aq. oxalic acid, RT, 1 h, 89 %.](ANGE-127-4118-g005){#sch4}

Assembly of **17 a**/**b** began with an Schreiber ozonolysis[13](#bib13){ref-type="ref"} of cyclohexene to give acetal **18**. Horner--Wadsworth--Emmons (HWE) olefination of **18** using phosphonate **19** provided **20** (8:1 mixture of inseparable *E*,*E*:*E*,*Z* isomers, Scheme [4](#sch4){ref-type="fig"}). The acid‐mediated deprotection of **20** gave dienal **21**, which was reacted with Wittig reagent **22**, followed by acetal hydrolysis to give the trienal **23** (85 % *E*,*E*,*E* geometry). Trienal **23** was then subjected to an organocatalytic intramolecular Diels--Alder (IMDA) reaction using MacMillan's conditions (Scheme [5](#sch5){ref-type="fig"}).[14](#bib14){ref-type="ref"} Both enantiomers of **24** were accessed with good enantioselectivities (see Scheme [5](#sch5){ref-type="fig"} and the Supporting Information for chiral GC analysis). The minor *E*,*Z*,*E* isomer present in the sample of **23** was inert in this IMDA reaction, thus enabling the purification to give either **24 a** or **24 b**, depending on which enantiomer of the organocatalyst was used (Scheme S4).[14](#bib14){ref-type="ref"} Elaboration of **24 a** and **24 b** to give β‐ketothioesters **17 a** and **17 b**, respectively, was achieved through an aldol reaction using *S*‐*tert*‐butyl thioacetate to give **25 a** or **25 b**, respectively, as an inconsequential mixture of diastereomers, followed by oxidation with Dess--Martin periodinane[15](#bib15){ref-type="ref"} (Scheme [5](#sch5){ref-type="fig"}).

![Synthesis of β‐ketothioesters **17 a** (Scheme [3](#sch3){ref-type="fig"}) and **17 b**. Reagents and conditions: a) 20 mol % (*S*,*S*)‐imidazolidinone TfOH, MeCN (2 % H~2~O), −5 °C, 48 h, 65 %, 87 % *ee*, d.r. 4:1. b) 20 mol % (*R*,*R*)‐imidazolidinone TfOH, MeCN (2 % H~2~O), −5 °C, 48 h, 68 %, 84 % *ee*, d.r. 4:1. c) (i) LDA, *S*‐*tert*‐butyl‐thioacetate, THF, −78 °C, 30 mins. (ii) **24 a**/**24 b**, THF, −78 °C, 2 h, **25 a** (66 %); **25 b** (69 %). d) Dess--Martin periodinane, DCM, RT, 2 h, **17 a** (79 %); **17 b** (82 %).](ANGE-127-4118-g002){#sch5}

The final stages involved a silver trifluoroacetate mediated coupling of **12** with either enantiomer of fragment **17** to give **26 a** and **26 b**, following the protocol developed by the Ley group for the synthesis of equisetin (Scheme [6](#sch6){ref-type="fig"}).[1b](#bib1b){ref-type="ref"}, [16](#bib16){ref-type="ref"} Finally, cyclization onto the lactone in **26 a** and **26 b** and microwave‐assisted ester hydrolysis gave separate samples of the optically enriched diastereomers **2 a** and **2 b**, which were purified by reverse‐phase chromatography. No evidence of epimerization at the C5' position was observed.[17](#bib17){ref-type="ref"}

![Synthesis of JBIR‐22 diastereomers **2 a** and **2 b**. Reagents and conditions: a) **12**, AgCF~3~CO~2~, Et~3~N, THF, 0 °C→RT, 2 h, **25 a**---89 %; **25 b**---84 %. b) (i) *t*BuOK, THF, 0 °C→RT, 2 h. (ii) Aq. NaOH, EtOH, 110 °C (MW), 20 mins, **2 a**---71 %; **2 b**---74 % over 2 steps.](ANGE-127-4118-g003){#sch6}

The assignment of the relative stereochemistry of **2** was completed by comparison of the reported spectroscopic data[2c](#bib2c){ref-type="ref"} for **2** with those obtained for our synthetic samples of **2 a** and **2 b**. This analysis revealed very similar ^1^H NMR signals, but clear differences in the ^13^C NMR spectra, with the signals reported for the isolated sample of **2** all being within ±0.1 ppm of those obtained for diastereomer **2 a**. In contrast, there were significant differences when the data was compared to that for diastereomer **2 b** (Figure [2](#fig2){ref-type="fig"} for selected examples and Table S2). Further evidence for the identical relative stereochemistry in **2** and diastereomer **2 a** came from doping experiments using UPLC‐TOFMS (Figure [2](#fig2){ref-type="fig"}). These studies showed that upon mixing of a sample of natural **2** (retention time=3.3 min) with **2 a**, an increase in the size of the peak at 3.3 min was observed, whereas doping of natural **2** with **2 b** led to the appearance of a different peak with a retention time of 3.6 min. Comparison of the specific rotation of **2 a** (![](ANGE-127-4118-e001.jpg "equation image")+75.0°, *c*=0.1, MeOH) with that obtained for natural **2** (![](ANGE-127-4118-e003.jpg "equation image")+62.0°, *c*=0.1, MeOH)[18](#bib18){ref-type="ref"} enabled the assignment of the absolute configuration of **2** as (2*S*, 3*S*, 6*R*, 11*S*, 5′*S*, 7′*S*).

![A) UPLC‐TOFMS doping experiment. B) Selected ^13^C NMR signals of **2 a** and **2 b** with **2 a**/**b** (a 1:1 mixture of **2 a** and **2 b** synthesized following an alternative route, Scheme S5). C) Selected ^1^H NMR signals of **2 a** and **2 b** with **2 a**/**b**. D) Selected ^13^C NMR chemical shifts of isolated **2** [2c](#bib2c){ref-type="ref"} and **2 a** and **2 b** (see Supporting Information for full table). UPLC‐TOFMS=ultra‐performance liquid chromatography coupled to time‐of‐flight mass spectrometry.](ANGE-127-4118-g007){#fig2}

In summary, a highly stereoselective synthesis of the masked 4,4‐disubstituted glutamic acid **12** enabled the first total synthesis of highly enantioenriched samples of two of the possible diastereomers of JBIR‐22 (**2**) by a concise, convergent strategy. The diastereomers **2 a** and **2 b** were synthesized in ten steps (longest linear route from cyclohexene) in 10.1 % and 11.3 % overall yield, respectively. The synthesis of two of the possible stereoisomers facilitated the assignment of both the relative and absolute configuration of the naturally occurring protein--protein interaction inhibitor **2**. The development of a short, stereoselective synthesis of **12** coupled with the convergent nature of this approach should facilitate the future synthesis and biological assessment of all members of this subfamily of natural products as well as novel analogues.
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